CEL-SCI Corp
AMEX:CVM
CEL-SCI Corp
Research & Development
CEL-SCI Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CEL-SCI Corp
AMEX:CVM
|
Research & Development
-$15.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
CEL-SCI Corp
Glance View
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
See Also
What is CEL-SCI Corp's Research & Development?
Research & Development
-15.9m
USD
Based on the financial report for Sep 30, 2025, CEL-SCI Corp's Research & Development amounts to -15.9m USD.
What is CEL-SCI Corp's Research & Development growth rate?
Research & Development CAGR 10Y
2%
Over the last year, the Research & Development growth was 13%. The average annual Research & Development growth rates for CEL-SCI Corp have been 14% over the past three years , 2% over the past five years , and 2% over the past ten years .
